Boston, USA-June 16. 2025 –Holy Stone Health Care (HSHC) is participating in the BIO International Convention (USBIO 2025) held in Boston from June 16 to June 19, presenting our HylX drug delivery platform and assets. During the event, we engage in partnership discussions with global pharmaceutical companies.

As one of the world’s leading forums for biotechnology innovation and business development, USBIO provides a critical platform to highlight our HylX drug delivery technology platform. Our core technology utilizes hyaluronic acid (HA) as drug carrier that facilitate drug penetration across biological barriers, enables targeted delivery, prolonged drug retention, reduced dosage and side effects, and offering a significant advancement in precision medicine.

We has scheduled one-on-one partnering meetings with leading global pharmaceutical companies to explore collaborations on drug delivery technologies for crossing the blood-brain barrier (BBB), blood-retina barrier (BRB), and tumor microenvironment (TME).

In addition, we will present our innovative drug candidates developed through the HylX platform, including:

• ND108E, for Alzheimer’s disease, utilizing BBB-penetrating delivery;
• IBD98-M, for ulcerative colitis, utilizing HA mucosal healing;
• CA102N, for solid tumor, utilizing stroma penetration.

By participating in USBIO 2025, we aim to strengthen international partnerships, broaden the global application of the HylX platform, and accelerate the clinical stage of assets.